DCTH vs. CDRE, TNDM, INMD, LQDA, KMTS, BLFS, MDXG, ESTA, FNA, and RXST
Should you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include Cadre (CDRE), Tandem Diabetes Care (TNDM), InMode (INMD), Liquidia (LQDA), Kestra Medical Technologies (KMTS), BioLife Solutions (BLFS), MiMedx Group (MDXG), Establishment Labs (ESTA), Paragon 28 (FNA), and RxSight (RXST). These companies are all part of the "medical equipment" industry.
Delcath Systems vs.
Delcath Systems (NASDAQ:DCTH) and Cadre (NYSE:CDRE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Delcath Systems has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Cadre has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.
Cadre has a net margin of 6.34% compared to Delcath Systems' net margin of -150.70%. Cadre's return on equity of 12.88% beat Delcath Systems' return on equity.
Delcath Systems received 17 more outperform votes than Cadre when rated by MarketBeat users. However, 55.17% of users gave Cadre an outperform vote while only 27.50% of users gave Delcath Systems an outperform vote.
Delcath Systems currently has a consensus price target of $22.75, indicating a potential upside of 61.18%. Cadre has a consensus price target of $37.00, indicating a potential upside of 17.37%. Given Delcath Systems' higher possible upside, equities analysts plainly believe Delcath Systems is more favorable than Cadre.
In the previous week, Cadre had 9 more articles in the media than Delcath Systems. MarketBeat recorded 10 mentions for Cadre and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.61 beat Cadre's score of 0.66 indicating that Delcath Systems is being referred to more favorably in the media.
Cadre has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.
61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 17.9% of Delcath Systems shares are held by company insiders. Comparatively, 37.0% of Cadre shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Cadre beats Delcath Systems on 11 of the 17 factors compared between the two stocks.
Get Delcath Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Delcath Systems Competitors List
Related Companies and Tools
This page (NASDAQ:DCTH) was last updated on 3/25/2025 by MarketBeat.com Staff